Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development

Go back to Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development

Achieve Life Sciences (ACHV) Tops Q3 EPS by 40c; Reports Cash and Cash Equivalents of $33.4M

November 9, 2021 4:56 PM EST

Achieve Life Sciences (NASDAQ: ACHV) reported Q3 EPS of ($0.71), $0.40 better than the analyst estimate of ($1.11).

For earnings history and earnings-related data on Achieve Life Sciences (ACHV) click here.

... More